




CLAIMS

1. A compound of formula (I)



or a pharmaceutically acceptable salt thereof, wherein:

-G₁ is a radical selected from (IIa) y (IIb);




wherein -R' is an electron pair or a (C₁-C₃)-alkyl radical; with the condition that



(i) when -R' is an electron pair, a is a N=C double bond and the fused ring




is the biradical





thus radicals (IIa) and (IIb) are respectively (IIa') and (IIb'), and



(ii) when $-R'$ is a (C_1-C_3) -alkyl radical, \underline{a} is a N-C single bond and the fused ring is the triradical



thus radicals (IIa) and (IIb) are respectively (IIa'') and (IIb'');



wherein $-R_1$ to $-R_{12}$ represent radicals, same or different, selected from the group consisting of H, (C_1-C_4) -alkyl, (C_1-C_4) -alkoxy, (C_1-C_4) -alkylamino, phenyl, F, Cl, Br, amino, hydroxy, and nitro;

and wherein $-B-$ is a biradical selected from the group consisting of $-\text{CONH}-$, $-\text{NR}_3-$, $-\text{O}-$, $-(\text{CH}_2)_n\text{NH}-$, $-(\text{CH}_2)_n\text{O}-$, $-\text{CONH}(\text{CH}_2)_v\text{Z}-$,

$-\text{CONH}(\text{CH}_2)_u\text{CH}(\text{CH}_2\text{OH})\text{CH}_2\text{Z}-$, and $-\text{CO}[\text{NHCHR}''\text{CO}]_m\text{O}-$; wherein $-\text{R}_{13}$ is selected from the group consisting of H, (C_1-C_4) -alkyl, (C_1-C_4) -alkoxy and (C_1-C_4) -alkylamino; $-\text{R}''$ are side chains radicals, same or different, corresponding to natural aminoacids; u is an integer from 1 to 3; m is an integer from 1 to 3; u is an integer from 1 to 3, and $-\text{Z}-$ is a biradical of a oligonucleotide phosphate between 4 and 23 bases in length, linked to the methylene group at the 5' end or at the 3' end;

$-\text{L}-$ is a single covalent bond or a covalent linking biradical selected from the following ones;

$-(\text{CH}_2)_r\text{NR}'''(\text{CH}_2)_s-$

$-(\text{CH}_2)_r\text{NR}'''(\text{CH}_2)_s\text{NR}'''(\text{CH}_2)_t-$


wherein $-\text{R}'''$ and $-\text{R}'''$ are radicals, same or different, selected from the group consisting of H and (C_1-C_3) -alkyl; r is an integer from 1 to 3; s is an integer from 1 to 3; t is an integer from 1 to 3; and

$-\text{G}_2$ is a radical selected from H, a radical of formula (IIa), a radical of formula (IIb), the N-radical of 1,8-naphthalimide, the C4-radical of 2-phenylquinoline, and the C9-radical of acridine;

with the proviso that (I) or its pharmaceutically acceptable salts is not one of the following compounds:

10H-quindoline-11-carboxamide;
 2-bromo-10H-quindoline-11-carboxamide;
 N-10H-quindolin-11-yl-1,3-propanediamine;
 10H-quindolin-11-amine monohydrochloride;
 10H-quindolin-11-methanol; or
 N-[2-(dimethylamino)-ethyl]-10H-quindoline-4-carboxamide.


2. The compound according to claim 1, wherein (IIa) is the radical (IIa').



3. The compound according to claim 2, wherein -B- is selected from the group consisting of -CONH- and -NR₁₃- .
4. The compound according to claim 2, wherein -B- is -CO[NHCHR''CO]_mO- .
5. The compound according to claim 4, wherein m = 2, the leftward -R'' is a glycine side chain, and the rightward -R'' is a arginine side chain.
6. The compound according to claim 2, wherein -B- is selected from the group consisting of -CONH(CH₂)_uZ- and -CONH(CH₂)_uCH(CH₂OH)CH₂Z- .
7. The compound according to claim 6, wherein -Z- is selected from the group consisting of -TTCCGGAA- linked to the methylene group at the 3' or at the 5' end, and -CTTCTTCTTCT- linked at the 3' end.
8. The compound according to any of the claims 2-7 wherein -L- is a single covalent bond.
9. The compound according to any of the claims 2-7, wherein -L- is a covalent linking biradical selected from the following ones.
 -(CH₂)_rNR'''(CH₂)_s-
 -(CH₂)_rNR'''(CH₂)_sNR'''(CH₂)_t-
10. The compound according to claim 9, wherein -L- is the biradical -(CH₂)_rNR'''(CH₂)_s- , -R''' is methyl, and both r and s are 3.

11. The compound according to claim 9, wherein -L- is the covalent linking biradical - $(\text{CH}_2)_r\text{NR}'''(\text{CH}_2)_s\text{NR}''''(\text{CH}_2)_t-$, both -R''' and -R'''' are methyl; both r and t are 2, and s is 2 or 3.

12. The compound according to claim 1, wherein (IIa) is the radical (IIa'').



13. The compound according to claim 12, wherein -B- is selected from the group consisting of -CONH- and -NR₁₃-.

14. The compound according to claim 12, wherein -B- is -CO[NHCHR''CO]_mO-.

15. The compound according to claim 14, wherein $m = 2$, the leftward -R'' is a glycine side chain, and the rightward -R'' is the arginine side chain.

16. The compound according to claim 12, wherein -B- is selected from the group consisting of -CONH(CH₂)_uZ- and -CONH(CH₂)_uCH(CH₂OH)CH₂Z-.


17. The compound according to claim 16, wherein -Z- is selected from the group consisting of -TTCCGGAA- linked to the methylene group at the 3' or at the 5' end, and -CTTCTTCTTCT- linked at the 3' end.

18. The compound according to any of the claims 12-17, wherein -R' is methyl.

19. The compound according to claim 18, wherein -L- is a single covalent bond.

20. The compound according to claim 18, wherein -L- is a biradical selected from the following ones.





21. The compound according to claim 20, wherein -L- is the biradical $-(\text{CH}_2)_r\text{NR}^{\text{'''}}(\text{CH}_2)_s-$, $\text{R}^{\text{'''}}$ is methyl, and both r and s are 3.

22. The compound according to claim 20, wherein -L- is the biradical $-(\text{CH}_2)_r\text{NR}^{\text{'''}}(\text{CH}_2)_s\text{NR}^{\text{''''}}(\text{CH}_2)_t-$, both $\text{R}^{\text{'''}}$ and $\text{R}^{\text{''''}}$ are methyl; both r and t are 2, and s is an integer from 2 to 3.

23. The compound according to claim 1, which is selected from the group consisting of:

- a) N-[3-[[3-[(9-acridinecarbonyl)amino]propyl]methylamino]propyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ia);
- b) N,N'-(4-methyl-4-azaheptamethylene)-di-(10H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Ib);
- c) N-[3-[3-[[2-(1,3-dioxo-(2,3-dihydro)-1H-benzo[de]isoquinoliny]propyl]methylamino]propyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ic);
- d) N-[3-[[3-[(2-phenyl-4-quinolinecarbonyl)amino]propyl]methylamino]propyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Id);
- e) N,N'-(3,7-dimethyl-3,7-diazanonamethylene)-di-(10H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Ie);
- f) N-[(9-acridinecarbonyl)-3,7,10-triaza-3,7-dimethyldecyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (If);
- g) N,N'-(3,6-dimethyl-3,6-diazaoctamethylene)-di-(10H-indolo[3,2-b]quinoline-11,11'-carboxamide (Ig);
- h) N-[(9-acridinecarbonyl)-3,6-dimethyl-3,6-diazaoctamethylene]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ih);
- i) N-[[1,3-dioxo-(2,3-dihydro)-1H-benzo[de]isoquinolyl]-3,6-dimethyl-3,6-diazaoctamethylene]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ii);
- j) N-[[1,3-dioxo-(2,3-dihydro)-1H-benzo[de]isoquinolyl]-3,7,10-triaza-3,7-dimethyldecyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ij);
- k) N,N'-(4-methyl-4-azaheptamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-carboxamide);
- l) 10H-indolo[3,2-b]quinoline-11-carbonyl-glicine-arginine;
- m) N,N-dimethyl-N'-(5-methyl-5H-indolo[3,2-b]quinolin-11-yl)-ethane-1,2-diamine (Ip);
- n) N,N'-(4-methyl-4-azaheptamethylen)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-amine (Iq);
- o) N-1-[(5-hydroxymethyl-6-(5'-TTCCGGAA-3'-phosphate)-hexyl)-10H-indolo[3,2-b]quinoline-11-carboxamide (Ir);

- p) N-1-[(5-hydroxymethyl-6-(5'-CTTCCTCCTCT-3'-phosphate)-hexyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Is);
- q) N-1-[6-(5'-phosphate-TTCCGGAA)-hexyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (It);
- r) 10H-Indolo[3,2-b]quinoline-11-carboxylic acid (2-dimethylamino-ethyl)amide (Iu);
- s) 10H-Indolo[3,2-b]quinoline-11-carboxylic acid (2-dimethylamino-propyl)amide (Iv);
- t) N,N-dimethyl-N'-(5-methyl-5H-indolo[3,2-b]quinolin-11-yl)-propane-1,2-diamine (Iw);
- u) N-[3-[[3-[(10H-indolo[3,2-b]quinoline-4-carboxamide]propyl)methylamino]propyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ix);
- v) N,N'-(3,7-dimethyl-3,7-diazanonamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Iy);
- w) N,N'-(3,6-dimethyl-3,6-diazaoctamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Iz);
- x) (3,7-diazanonamethylene)-di-(10H-indolo[3,2-b]quinoline-11,11'-carboxamide (Iaa);
- y) N,N'-(3,7-dimethyl-3,7-diazanonamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-amine (Iab); and
- z) N,N'-(3,6-dimethyl-3,6-diazaoctamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-amine (Iac).

24. Use of the compound as defined in any of the claims 1 to 23, for the preparation of a medicament for the treatment of cancer.

25. A pharmaceutical composition comprising a therapeutically effective amount of the compound as defined in any of the claims 1 to 23, together with appropriate amounts of pharmaceutical excipients or carriers.